Human NMI (N-Myc-Interactor) - Recombinant Protein
Beta LifeScience
SKU/CAT #: BLT-02043P
SDS-PAGE analysis of Human NMI (N-Myc-Interactor) - Recombinant Protein, CAT# BLT-02043P, showing >85% purity under 15% SDS-PAGE (Reduced)
Human NMI (N-Myc-Interactor) - Recombinant Protein
Beta LifeScience
SKU/CAT #: BLT-02043P
Regular price
$59500
$595.00
Sale price$54500
$545.00Save $50
/
Quantity Pricing
| Pack Size | Price (USD) |
|---|---|
| 500 µg | $1,375 |
| 1 mg | $2,245 |
For direct online orders, quantity pricing will be displayed in cart when you add 5x100ug or 10x100ug
Submit an inquiry or email inquiry@betalifesci.com for a customization request or bulk order quote.
Connect with us via the live chat in the bottom corner to receive immediate assistance.
Product Overview
| Product Name | Recombinant Human NMI Protein |
| Product Overview | This recombinant human NMI protein includes amino acids 1-307aa of the target gene is expressed in E.coli.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization. |
| Target Uniprot Id | Q13287 |
| Recommended Name | N-myc-interactor |
| Gene Name | NMI |
| Synonyms | N-myc-interactor |
| Species | Human |
| Predicted Molecular Mass | 37.2 kDa |
| Expression System | E.coli |
| Expression Range | 1-307aa |
| Tag | N-6His |
| Purity | >85% |
| Formulation | Lyophilized |
| Buffer | Phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose |
| Storage Condition | 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C. |
| Reconstitution Instruction | Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%. |
| Applications | Positive Control; Immunogen; SDS-PAGE; WB |
| Research Area | Epigenetics And Nuclear Signaling |
| Target Function | Acts as a signaling pathway regulator involved in innate immune system response. In response to interleukin 2/IL2 and interferon IFN-gamma/IFNG, interacts with signal transducer and activator of transcription/STAT which activate the transcription of downstream genes involved in a multitude of signals for development and homeostasis. Enhances the recruitment of CBP/p300 coactivators to STAT1 and STAT5, resulting in increased STAT1- and STAT5-dependent transcription. In response to interferon IFN-alpha, associates in a complex with signaling pathway regulator IFI35 to regulate immune response; the complex formation prevents proteasome-mediated degradation of IFI35. In complex with IFI35, inhibits virus-triggered type I IFN-beta production when ubiquitinated by ubiquitin-protein ligase TRIM21. In complex with IFI35, negatively regulates nuclear factor NF-kappa-B signaling by inhibiting the nuclear translocation, activation and transcription of NF-kappa-B subunit p65/RELA, resulting in the inhibition of endothelial cell proliferation, migration and re-endothelialization of injured arteries. Negatively regulates virus-triggered type I interferon/IFN production by inducing proteosome-dependent degradation of IRF7, a transcriptional regulator of type I IFN, thereby interfering with cellular antiviral responses. Beside its role as an intracellular signaling pathway regulator, also functions extracellularly as damage-associated molecular patterns (DAMPs) to promote inflammation, when actively released by macrophage to the extracellular space during cell injury or pathogen invasion. Macrophage-secreted NMI activates NF-kappa-B signaling in adjacent macrophages through Toll-like receptor 4/TLR4 binding and activation, thereby inducing NF-kappa-B translocation from the cytoplasm into the nucleus which promotes the release of proinflammatory cytokines. |
| Subcellular Location | Cytoplasm. Nucleus. Secreted. |
| Protein Family | NMI family |
| Tissue Specificity | Expressed in adult spleen, liver, and kidney. Expressed in fetal thymus, liver, placenta, spleen, lung, and kidney but not brain. Expressed in macrophages. |
